Abstract

Two extremely preterm infants undergoing intensive care who developed systemic candidiasis are reported. Each was treated initially with intravenous miconazole. One child initially responded, but relapsed after the miconazole was stopped. The second child showed evidence of progression of the disease during treatment. Both infants responded to a combined course of amphotericin B and 5-fluorocytosine. We consider that miconazole is not the drug of first choice in the treatment of neonatal systemic candidiasis.